EUVIMEDEUVIMED entdecken
Vergleichsstudie

A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma

Paola Ghione, M Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Jessica Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S Neelapu, Herve Ghesquieres, Myrna Nahas und 3 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024-05 · 24 (5) · e191-e195.e6

DOI: 10.1016/j.clml.2024.01.011 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-05. Verfasst von Paola Ghione und 14 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: ghionep@mskcc.org. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Biological Products. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularBiological ProductsHumansMaleFollow-Up StudiesFemaleMiddle AgedImmunotherapy, AdoptiveAgedAdultAntigens, CD19Treatment OutcomeNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Axi-celCAR T-cellEfficacyIndirect treatment comparisonNon-Hodgkin's lymphoma

Substanzen

axicabtagene ciloleucelBiological ProductsAntigens, CD19

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: ghionep@mskcc.org.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Kite, a Gilead Company, Santa Monica, CA.
  • RainCity Analytics, Vancouver, BC, Canada.
  • Delta Hat, Nottingham, UK.
  • Vall D'Hebron Insitute of Oncology, Barcelona, Spain.

Zitieren

APA

Ghione, P., Palomba, M. L., Ray, M. D., Limbrick-Oldfield, E. H., Owen, J., Kanters, S., Bobillo, S., Ribiero, M. T., Jacobson, C. A., Neelapu, S. S., Ghesquieres, H., Nahas, M., Beygi, S., Patel, A. R., & Gribben, J. G. (2024). A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 24(5), e191-e195.e6. https://doi.org/10.1016/j.clml.2024.01.011

Vancouver

Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, et al. A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2024;24(5):e191-e195.e6. doi:10.1016/j.clml.2024.01.011

BibTeX
@article{Ghione2024,
  author = {Ghione, Paola and Palomba, M Lia and Ray, Markqayne D and Limbrick-Oldfield, Eve H and Owen, Jessica and Kanters, Steve and Bobillo, Sabela and Ribiero, Maria Teresa and Jacobson, Caron A and Neelapu, Sattva S and Ghesquieres, Herve and Nahas, Myrna and Beygi, Sara and Patel, Anik R and Gribben, John G},
  title = {A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {5},
  pages = {e191--e195.e6},
  doi = {10.1016/j.clml.2024.01.011}
}
Kostenlos starten →